Showing results (361-370 of 470) with videos related to

Sort By:
Pageof 47
Leukemia & Lymphoma|December 26, 2025
Treatment kinetics and local response during and after bridging radiotherapy prior to CAR-T cell therapy for lymphomasDaniella Klebaner, Natalie J Park, Mallika Marar, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|May 3, 2011
A randomized, double-blind, placebo-controlled, phase II study of oral talactoferrin in combination with carboplatin and paclitaxel in previously untreated locally advanced or metastatic non-small cell lung cancerRaghunadharao Digumarti, Yenyun Wang, Ganapathi Raman, et al.
Blood|January 10, 2015
Brentuximab vedotin demonstrates objective responses in a phase 2 study of relapsed/refractory DLBCL with variable CD30 expressionEric D Jacobsen, Jeff P Sharman, Yasuhiro Oki, et al.
Asia-Pacific Journal of Clinical Oncology|November 27, 2012
A multicenter phase II randomized study of Cremophor-free polymeric nanoparticle formulation of paclitaxel in women with locally advanced and/or metastatic breast cancer after failure of anthracyclineAnantbhushan A Ranade, Poonamalle P Bapsy, Shona Nag, et al.
Leukemia & Lymphoma|July 27, 2016
The Pattern of Malignant Lymphoma in India: A Study of 1371 CasesS H Advani, S D Banavali, S Agarwala, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 11, 2010
In situ vaccination with a TLR9 agonist induces systemic lymphoma regression: a phase I/II studyJoshua D Brody, Weiyun Z Ai, Debra K Czerwinski, et al.
The American Journal of Surgical Pathology|August 24, 2022
Targeted Mutational Profiling Reveals Clonal Relationships in Metachronous Occurrence of Classic Hodgkin and Mediastinal Large B-Cell LymphomasKunwar Singh, Lhara S Lezama, Jason Kurzer, et al.
Blood|March 7, 2018
Five-year outcomes for frontline brentuximab vedotin with CHP for CD30-expressing peripheral T-cell lymphomasMichelle A Fanale, Steven M Horwitz, Andres Forero-Torres, et al.
Blood Advances|July 17, 2025
Long-term follow-up of venetoclax monotherapy in previously treated patients with Waldenström macroglobulinemiaJorge J Castillo, Alberto Guijosa, John N Allan, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 8, 2016
Phase I Study of the Anti-CD22 Antibody-Drug Conjugate Pinatuzumab Vedotin with/without Rituximab in Patients with Relapsed/Refractory B-cell Non-Hodgkin LymphomaRanjana H Advani, Daniel Lebovic, Andy Chen, et al.
Pageof 47